2024-10-29 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**1. Performance and Relative Strength:**

AbbVie Inc. (ABBV) has outperformed the S&P 500 (VOO) over the period analyzed.  The cumulative return for ABBV is 146.54%, while the S&P 500 has returned 136.36%, representing a difference of 10.18%. This puts ABBV's current relative performance at the 52.23 percentile, meaning it has outperformed the S&P 500 more than 50% of the time during this period.

**2. Recent Price Action:**

* **Closing Price:** 189.68 (Last Market: 189.74)
* **5-Day Moving Average:** 188.76
* **20-Day Moving Average:** 191.96
* **60-Day Moving Average:** 193.23

Currently, the stock is trading slightly below its 5-day moving average, indicating potential downward pressure.  The 20-day and 60-day moving averages are above the current price, suggesting a possible trend reversal.

**3. Technical Indicators:**

* **RSI:** 42.41
* **PPO:** -0.2
* **Delta_Previous_Relative_Divergence:** -11.87 (-) - Short-term downtrend
* **Expected Return:** 3.04% - This represents the projected long-term (2 years+) excess return compared to the S&P 500, assuming a consistent investment strategy.

The RSI indicates a slightly oversold condition, while the PPO suggests a potential short-term downtrend. The negative Delta_Previous_Relative_Divergence reinforces this short-term bearish sentiment. 

**4. Recent Earnings and Outlook:**

| Date        | EPS     | Expected EPS |
|-------------|---------|---------------|
| 2024-07-25 | 2.65    | 2.57          |
| 2024-04-26 | 2.31    | 2.26          |
| 2024-02-02 | 2.79    | 2.76          |
| 2023-10-27 | 2.95    | 2.86          |
| 2023-07-27 | 2.91    | 2.79          |

AbbVie has consistently exceeded analysts' EPS expectations in recent quarters. The most recent earnings report showed a strong beat with EPS of 2.65, exceeding expectations by 3%.  This suggests positive momentum and continued growth potential for the company. 

**5. Financial Trends Analysis:**

| Item               | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|--------------------|---------------|---------------|---------------|
| Revenue            | $14.46B         | $12.31B         | $14.30B         | 
| Gross Profit       | $10.26B         | $8.22B          | $8.60B          | 
| Gross Margin %     | 70.94%          | 66.74%          | 60.11%          | 
| Operating Income   | $4.93B          | $2.96B          | $3.48B          | 
| Operating Margin % | 34.12%          | 24.06%          | 24.31%          | 
| Net Income         | $1.37B          | $1.37B          | $0.82B          | 
| Net Margin %       | 9.47%           | 11.12%          | 5.75%           | 
| EPS                | $0.78           | $0.78           | $0.47           | 
| ROE %              | 20.21%          | 17.10%          | 7.93%           | 
| Total Assets       | $141.94B        | $148.87B        | $134.71B        | 
| Total Liabilities  | $135.12B        | $140.83B        | $124.31B        | 
| Total Equity       | $6.78B          | $8.01B          | $10.36B         | 
| Operating Cash Flow | $2.27B          | $4.04B          | $4.75B          | 
| Capital Expenditure | $-0.24B         | $-0.19B         | $-0.20B         | 

AbbVie's financial performance shows strong revenue growth and profitability, with a consistent gross margin exceeding 60%. The company also maintains a healthy operating cash flow and consistently invests in capital expenditures.  

**6. News and Recent Issues:**

(Please provide specific dates and information about any relevant news, earnings reports, or other announcements within the last 2 days. Include details regarding recent market outlook for ABBV, analyst opinions, and performance highlights. You can use sources like Shacknews, FINBOLD, and others.)

**7. Overall Analysis:**

AbbVie Inc. (ABBV) shows solid financial performance, with consistent revenue growth and exceeding analysts' expectations in recent earnings reports.  The company is well-positioned with a strong operating cash flow and continued investments in capital expenditures.  While current market conditions are showing a short-term downtrend, ABBV's long-term potential for exceeding the S&P 500 returns remains positive.

**Please note:** This is a basic analysis of ABBV. For a more comprehensive evaluation, consider consulting with a financial professional and conducting your own due diligence.